NEW YORK, Feb. 3 (GenomeWeb News) - Genome Therapeutics has set a price of $5.25 per share for the sale of up to 16.8 million shares of its common stock, the company said today.

The offering will fund the pending acquisition of Genesoft Pharmaceuticals, which was approved by the shareholders of both firms yesterday. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.